Stockscreener 앱 받기
5.37%
시장 영업 전:
전일 마감가:
$1.49
열려 있는:
$1.485
하루 거래량:
14.43M
Relative Volume:
1.19
시가총액:
$1.02B
수익:
$29.48M
순이익/손실:
$-201.19M
주가수익비율:
-4.4063
EPS:
-0.32
순현금흐름:
$-216.50M
1주 성능:
-0.70%
1개월 성능:
-7.24%
6개월 성능:
-60.17%
1년 성능:
-66.75%
1일 변동 폭
$1.3646
$1.485
1주일 범위
$1.3646
$1.57
52주 변동 폭
$1.17
$5.06
제론 Stock (GERN) Company Profile
명칭
Geron Corp
전화
(650) 473-7700
주소
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
GERN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.41 | 1.02B | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
제론 Stock (GERN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-08 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-02-27 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2025-02-26 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 개시 | Leerink Partners | Outperform |
| 2024-04-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-04-29 | 개시 | TD Cowen | Buy |
| 2024-03-15 | 재확인 | Needham | Buy |
| 2023-09-12 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-28 | 개시 | Goldman | Neutral |
| 2022-10-28 | 개시 | Wedbush | Outperform |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2021-11-02 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 재개 | B. Riley Securities | Buy |
| 2020-08-03 | 개시 | Stifel | Buy |
| 2019-11-19 | 재개 | B. Riley FBR | Buy |
| 2019-09-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-04-09 | 업그레이드 | Needham | Hold → Buy |
| 2019-01-31 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-10-02 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-07-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2016-09-13 | 재확인 | FBR & Co. | Outperform |
| 2016-09-13 | 재확인 | FBR Capital | Outperform |
| 2015-12-07 | 재확인 | Piper Jaffray | Overweight |
| 2015-04-21 | 개시 | Oppenheimer | Outperform |
| 2014-06-12 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-03-12 | 다운그레이드 | MLV & Co | Buy → Hold |
| 2013-12-10 | 재확인 | MLV & Co | Buy |
| 2013-12-10 | 업그레이드 | Needham | Hold → Buy |
| 2013-11-08 | 재확인 | MLV & Co | Buy |
| 2013-10-16 | 개시 | MLV & Co | Buy |
| 2012-08-30 | 개시 | Stifel Nicolaus | Buy |
| 2012-06-28 | 개시 | Needham | Hold |
모두보기
제론 주식(GERN)의 최신 뉴스
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
With 65% institutional ownership, Geron Corporation (NASDAQ:GERN) is a favorite amongst the big guns - Yahoo Finance
Geron: A Tough First Year For Rytelo, But Not Yet Time To Sell (Downgrade) (NASDAQ:GERN) - Seeking Alpha
Geron Q1 2025 slides: RYTELO growth plans amid revenue challenges - Investing.com
Geron Q1 2025 slides: RYTELO growth plans amid revenue challenges By Investing.com - Investing.com Canada
Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights - mx.advfn.com
Class Action Filed Against Geron Corporation (GERN)May 12, 2025 Deadline to JoinContact The Gross Law Firm - mx.advfn.com
Conservative Vision Of A Positive Future For Geron (NASDAQ:GERN) - Seeking Alpha
Nuveen Asset Management LLC Purchases 14,657 Shares of Geron Co. (NASDAQ:GERN) - Defense World
Geron showcases RYTELO benefits at oncology meetings By Investing.com - Investing.com South Africa
Geron’s SWOT analysis: oncology firm’s stock faces growth hurdles By Investing.com - Investing.com South Africa
Geron showcases RYTELO benefits at oncology meetings - Investing.com
Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program - Yahoo Finance
Geron’s SWOT analysis: oncology firm’s stock faces growth hurdles - Investing.com
Geron Corp stockholders approve equity plan amendments By Investing.com - Investing.com India
Geron Corp stockholders approve equity plan amendments - Investing.com
BNP Paribas Financial Markets Decreases Stock Holdings in Geron Co. (NASDAQ:GERN) - Defense World
25,148 Shares in Geron Co. (NASDAQ:GERN) Purchased by Lazard Asset Management LLC - Defense World
Geron Co. (NASDAQ:GERN) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Bank of America Corp DE Boosts Stock Position in Geron Co. (NASDAQ:GERN) - Defense World
Ameriprise Financial Inc. Buys 247,018 Shares of Geron Co. (NASDAQ:GERN) - Defense World
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GERN Stock News - GuruFocus
Geron Grants $522K Worth of Stock Options and RSUs: New Employee Compensation Details Revealed - Stock Titan
Stifel Financial Corp Increases Position in Geron Co. (NASDAQ:GERN) - Defense World
Geron Corp Stock (GERN): Demand Recovery on the Rise - Value The Markets
Northern Trust Corp Has $19.76 Million Stake in Geron Co. (NASDAQ:GERN) - Defense World
Why Geron Corporation (GERN) Is The Best Low Priced Biotech Stock to Buy Now - Insider Monkey
Geron Corporation Investors: Please contact the Portnoy Law - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - Business Wire
GERN Investors are Reminded of an Opportunity to Lead Geron Corp - GuruFocus
10 Best Low Priced Biotech Stocks to Buy Now - Insider Monkey
GERN Investors are Reminded of an Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm - Benzinga
Geron outlines strategies to boost RYTELO adoption and anticipates Phase III myelofibrosis trial results in 2026 - MSN
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron LawsuitGERN - Stockhouse
Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - GlobeNewswire
Research Analysts Set Expectations for Geron FY2028 Earnings - Defense World
Analysts Have Lowered Expectations For Geron Corporation (NASDAQ:GERN) After Its Latest Results - simplywall.st
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 3D Systems Corporation - GlobeNewswire Inc.
Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade) - Seeking Alpha
Lost Money on Geron Corporation (GERN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Stockhouse
Geron slips as Scotiabank downgrades on sales challenges for blood cancer drug - MSN
Geron (GERN) Faces Downgrade Amid Rytelo Rollout Concerns - GuruFocus
Geron stock is downgraded at Scotiabank (GERN:NASDAQ) - Seeking Alpha
Geron (GERN) Price Target Reduced by Wedbush Amid Uptake Challen - GuruFocus
Geron (GERN) Experiences Notable Downgrade from Scotiabank | GER - GuruFocus
Geron Corporation (NASDAQ:GERN) Q1 2025 Earnings Call Transcript - Insider Monkey
Geron (GERN) Experiences Notable Downgrade from Scotiabank | GERN Stock News - GuruFocus
Geron (GERN) Faces Downgrade Amid Rytelo Launch Challenges | GERN Stock News - GuruFocus
Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for InvestorsContact Levi & Korsinsky - Stockhouse
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Geron Corporation(GERN) Shareholders - PR Newswire
Geron Corp (GERN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic ... - Yahoo Finance
제론 (GERN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
제론 주식 (GERN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Samuels Scott Alan | EVP, Chief Legal Officer |
Feb 27 '25 |
Buy |
1.61 |
15,000 |
24,150 |
26,682 |
| SCARLETT JOHN A | Chairman, President and CEO |
Feb 27 '25 |
Buy |
1.76 |
12,500 |
22,062 |
12,500 |
| Ziegler James | EVP, Chief Commercial Officer |
Feb 27 '25 |
Buy |
1.60 |
100,000 |
160,000 |
100,000 |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Option Exercise |
1.72 |
674,348 |
1,159,879 |
674,348 |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Sale |
4.56 |
674,348 |
3,073,004 |
0 |
0.78%
0.23%
자본화:
|
볼륨(24시간):